Effects of terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, on retinal vascularity in diabetic rats

被引:7
|
作者
De La Cruz, J. P. [1 ]
Jebrouni, N. [1 ]
Lopez-Villodres, J. A. [1 ]
Munoz-Marin, J. [1 ]
Guerrero, A. [1 ]
Gonzalez-Correa, J. A. [1 ]
机构
[1] Univ Malaga, LIAIT, Dept Pharmacol & Therapeut, Sch Med, E-29071 Malaga, Spain
关键词
terutroban; diabetic retinopathy; endothelial dysfunction; platelets; THROMBOXANE SYNTHASE INHIBITOR; EXPERIMENTAL-MODEL; NITRIC-OXIDE; ENDOTHELIAL DYSFUNCTION; S18886; ASPIRIN; PROSTACYCLIN; PATTERN; ATHEROSCLEROSIS; ATHEROGENESIS;
D O I
10.1002/dmrr.1283
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The aim of the present study is to investigate the effectiveness of terutroban, a selective antagonist of the thromboxane/prostaglandin endoperoxide receptor, in preventing retinal ischaemia in a model of diabetes in rats. Methods Experimental diabetes was induced with streptozotocin. Rats were distributed into five groups (n=20): (1) non-diabetic rats, (2) rats with diabetes (DR) treated with vehicle, (3) DR treated with aspirin (2mg/kg/day p.o.), (4) DR treated with terutroban (5mg/kg/day p.o.), (5) DR treated with terutroban (30 mg/kg/day p.o.). The follow-up period was 3 months. The main assessment was the percentage of retinal surface covered with vessels permeable to peroxidase. Platelet aggregation, aortic prostacyclin and nitric oxide production, plasma levels of lipid peroxides (thiobarbituric-acid-reactive substances) and 3-nitrotyrosine and serum levels of IL-6 were evaluated. Results Diabetes induced a reduction in retinal vascularity (76.9%), aortic prostacyclin (37.8%) and nitric oxide production (35.0%), and increased platelet aggregation, lipid peroxides, 3-nitrotyrosine. When compared with vehicle-treated DR, terutroban increased the percentage of retinal surface covered by PVPP (38% for terutroban-5 and 61% for terutroban-30), aortic prostacyclin (188% for terutroban-5 and 146% for terutroban-30) and nitric oxide production (320% for terutroban-5 and 390% for terutroban-30). Moreover, terutroban reduced platelet reactivity (27.8-95.1%, according to the inducer), lipid peroxides (60.7% for terutroban-5 and 50.0% for terutroban-30), 3-nitrotyrosine (43.8% for terutroban-5 and 36.8% for terutroban-30) and IL-6 concentration (18.0% for terutroban-30). The effect of terutroban in retinal, nitrosative and aortic parameters was significantly higher than that of aspirin. Conclusions Terutroban significantly protected retinal vascularity from ischaemia in experimental diabetes, and this result could be attributed not only to its antiplatelet/antithrombotic activities but also to its vascular properties. Copyright (C) 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:132 / 138
页数:7
相关论文
共 50 条
  • [31] ANTITHROMBOTIC EFFECTS OF RIDOGREL, A COMBINED THROMBOXANE-A2 SYNTHASE INHIBITOR AND PROSTAGLANDIN ENDOPEROXIDE-RECEPTOR ANTAGONIST, IN A PLATELET-MEDIATED CORONARY-ARTERY OCCLUSION PREPARATION IN THE DOG
    YASUDA, T
    GOLD, HK
    YAOTIA, H
    GUERRERO, JL
    HOLT, RE
    FALLON, JT
    LEINBACH, RC
    COLLEN, D
    CORONARY ARTERY DISEASE, 1991, 2 (10) : 1103 - 1110
  • [32] THROMBOXANE-A2 AND PROSTAGLANDIN ENDOPEROXIDE ANALOG EFFECTS ON PORCINE RENAL BLOOD-FLOW
    CIRINO, M
    MORTON, H
    MACDONALD, C
    HADDEN, J
    FORDHUTCHINSON, AW
    AMERICAN JOURNAL OF PHYSIOLOGY, 1990, 258 (01): : F109 - F114
  • [33] HA-29 - AN INHIBITOR OF THROMBOXANE-A2 FORMATION WITH ANTAGONISM OF THROMBOXANE-A2 PROSTAGLANDIN ENDOPEROXIDE RECEPTOR IN RABBIT PLATELETS
    LIN, CH
    KUO, SC
    HUANG, LJ
    HUANG, TF
    TENG, CM
    THROMBOSIS RESEARCH, 1992, 66 (01) : 61 - 73
  • [34] PHARMACOLOGICAL PROFILE OF BMS-180,291 - A POTENT, LONG-ACTING, ORALLY ACTIVE THROMBOXANE-A2/PROSTAGLANDIN-ENDOPEROXIDE RECEPTOR ANTAGONIST
    OGLETREE, ML
    HARRIS, DN
    SCHUMACHER, WA
    WEBB, ML
    MISRA, RN
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1993, 264 (02): : 570 - 578
  • [35] THE EFFECTS OF L655,240, A SELECTIVE THROMBOXANE AND PROSTAGLANDIN ENDOPEROXIDE ANTAGONIST, ON ISCHEMIA-INDUCED AND REPERFUSION-INDUCED CARDIAC-ARRHYTHMIAS
    WAINWRIGHT, CL
    PARRATT, JR
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1988, 12 (03) : 264 - 271
  • [36] ADENOSINE PRODUCES PULMONARY VASOCONSTRICTION IN SHEEP - EVIDENCE FOR THROMBOXANE-A2 PROSTAGLANDIN ENDOPEROXIDE-RECEPTOR ACTIVATION
    BIAGGIONI, I
    KING, LS
    ENAYAT, N
    ROBERTSON, D
    NEWMAN, JH
    CIRCULATION RESEARCH, 1989, 65 (06) : 1516 - 1525
  • [37] PROSTAGLANDIN-E2-INDUCED CONTRACTIONS OF CANINE PULMONARY VEINS ARE MEDIATED THROUGH THE THROMBOXANE/ENDOPEROXIDE RECEPTOR
    CISHEK, ME
    SPRAGUE, RS
    STEPHENSON, AH
    WURTZ, MM
    WEINTRAUB, NL
    LONIGRO, AJ
    CLINICAL RESEARCH, 1991, 39 (03): : A751 - A751
  • [38] EFFECT OF E5510 ON THROMBOXANE-A2 PROSTAGLANDIN ENDOPEROXIDE RECEPTOR MEDIATED PLATELET ACTIVATION INVITRO
    KOGUSHI, M
    HARADA, K
    SAEKI, T
    SAITOH, I
    FUJIMORI, T
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (02) : 337 - 338
  • [39] 13-AZAPROSTANOIC ACID - SPECIFIC ANTAGONIST OF THE HUMAN-BLOOD PLATELET THROMBOXANE-ENDOPEROXIDE RECEPTOR
    LEBRETON, GC
    VENTON, DL
    ENKE, SE
    HALUSHKA, PV
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (08) : 4097 - 4101
  • [40] DIFFERENTIAL-EFFECTS OF DAZOXIBEN, A SELECTIVE THROMBOXANE SYNTHASE INHIBITOR, ON PLATELET AND RENAL PROSTAGLANDIN ENDOPEROXIDE METABOLISM
    PATRIGNANI, P
    FILABOZZI, P
    CATELLA, F
    PUGLIESE, F
    PATRONO, C
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1984, 228 (02): : 472 - 477